Please assess the completion status of the following clinical trial:

Trial Title: Study of DITPA in Patients With Congestive Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than or equal to 18 years of age~* NYHA class III or IV CHF~* Females must not be pregnant or lactating. Females of childbearing potential and males must use a reliable means of contraception~* Serum total T3 \<= 95 ng/dL with normal levels of TSH~* On a regimen consisting of angiotensin-converting enzyme inhibitors and/or angiotensin receptor antagonists, beta blockers, and diuretics for a minimum of 3 months prior to randomization~* Clinically stable for 2 weeks prior to randomization (defined as no change in functional class by NYHA, no hospitalization or ER visit, and no intravenous inotropic or vasodilator treatment for 2 weeks)~* An LVEF \<= 40%, documented within 6 months prior to randomization, or \> 6 months with confirmation of LVEF by local echocardiographic measurements within 2 weeks prior to randomization~* Able to give informed consent~Exclusion Criteria:~* New onset CHF (less than 3 months prior to randomization)~* Active myocarditis, hypertrophic cardiomyopathy, uncorrected primary valvular disease, restrictive cardiomyopathy, uncorrected congenital heart disease, or constrictive pericarditis~* Myocardial infarction, unstable ischemic heart disease, stroke, or coronary revascularization procedure within 4 weeks prior to randomization; or an expectation of a coronary revascularization procedure, cardiac transplant, or left ventricular assist device placement being needed within 24 weeks after randomization~* History of sudden arrhythmic syncope or sustained ventricular arrhythmia, unless the patient has an implantable cardioverter defibrillator (ICD) for at least 12 weeks prior to randomization; history of clinically significant heart block, unless the patient has had a pacemaker at least 12 weeks prior to randomization~* History of cardiac resynchronization therapy in the last 12 weeks prior to randomization or expectation of cardiac resynchronization therapy or ventricular mechanical assistance needed within 24 weeks after randomization~* History of cardiac transplant~* Heart rate \< 50 beats per minute or \> 130 beats per minute~* Systolic blood pressure \<= 80 mm Hg~* Serum creatinine =\> 2.5 mg/dL~* Treatment with intravenous vasodilators (including nesiritide) or inotropes within 2 weeks prior to randomization~* Receipt of any other investigational agent or device within 4 weeks prior to randomization~* Diagnosis of other non-cardiac underlying medical conditions expected to impact their mortality within 24 weeks after randomization~* Drug or alcohol dependence, or other conditions which may affect study compliance~* History of thyroid disorders of any form within 24 weeks prior to randomization~* Use of thyroid supplements (levothyroxine, liothyronine, etc.) or any preparation containing thyromimetic agents within 24 weeks prior to randomization~* Supraventricular arrhythmia refractory to conventional treatment, as judged by the investigators

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DITPA 180 mg/day (Type: EXPERIMENTAL): DITPA 180 mg/day BID
- DITPA 360 mg/day (Type: EXPERIMENTAL): DITPA 360 mg/day BID
- Placebo (Type: PLACEBO_COMPARATOR): Placebo BID

Based on this trial design, predict the completion outcome and termination type (if applicable).